This Desmoplastic Small Round Cell Tumor Treatment market report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
The desmoplastic small round cell tumor treatment market size has grown strongly in recent years. It will grow from $3.42 billion in 2023 to $3.7 billion in 2024 at a compound annual growth rate (CAGR) of 8.3%. The growth observed during the historical period can be attributed to increased awareness of rare cancers, a rise in the number of clinical trials, enhanced funding for rare cancer research, greater availability of advanced diagnostics, and the expansion of immunotherapies and gene therapies.
The desmoplastic small round cell tumor treatment market size is expected to see strong growth in the next few years. It will grow to $5.11 billion in 2028 at a compound annual growth rate (CAGR) of 8.4%. The anticipated growth during the forecast period can be attributed to the increasing number of specialized treatment centers, the rise of personalized medicine, a greater use of combination therapies, more new drug approvals, and an uptick in healthcare expenditures on cancer treatment. Key trends expected in this period include the adoption of targeted therapies, the integration of advanced diagnostics, the implementation of personalized medicine, advancements in gene editing technologies, and the development of improved drug delivery systems.
The growing emphasis on personalized medicine is projected to drive the growth of the desmoplastic small round cell tumor (DSRCT) treatment market in the future. Personalized medicine involves tailoring healthcare to an individual’s unique genetic profile, lifestyle, and environment. It encompasses strategies such as pharmacogenomics, targeted therapies, and gene editing to deliver more precise and effective treatments. The increasing focus on personalized medicine is fueled by advancements in genomics, enhanced patient outcomes, and the potential for more targeted therapies. In the case of DSRCT, personalized medicine enables treatment strategies that are based on the specific genetic and molecular characteristics of the tumor, facilitating targeted therapies that enhance efficacy and minimize side effects. For example, the Personalized Medicine Coalition, a US-based professional membership organization, reported that in 2022, the approval of 12 new personalized medicines accounted for approximately 34% of all new therapies approved, indicating a significant increase compared to previous years. Thus, the heightened focus on personalized medicine is a key driver of the DSRCT treatment market.
Increased investment in oncology research is also expected to support the growth of the desmoplastic small round cell tumor treatment market in the future. The rise in funding for oncology research is driven by the increasing incidence of cancer worldwide, advancements in precision medicine, and the need for innovative treatments to enhance patient outcomes. Research in oncology contributes to the treatment of DSRCT by improving the understanding of the tumor's biology, leading to the development of targeted therapies and better treatment protocols that improve patient outcomes. For instance, the National Cancer Institute, a US-based organization, reported in June 2024 that its budget for fiscal year 2022 was approximately $6.8 billion, reflecting a 5.7% increase from the previous year. Therefore, the growing investment in oncology research is propelling the DSRCT treatment market.
The increasing number of clinical trials is anticipated to drive the growth of the desmoplastic small round cell tumor treatment market moving forward. Clinical trials involve human volunteers and assess the safety and efficacy of new medical treatments or procedures, aiming to collect scientific data on their appropriateness for human use. The rise in clinical trials is largely attributed to advancements in medical research, the growing burden of diseases, regulatory changes, the globalization of clinical research, increased patient advocacy and awareness, competition within the industry, technological advancements, and new funding opportunities. Clinical trials provide access to innovative therapies and evaluate the effectiveness of new treatments, thereby improving patient outcomes and promoting the development of targeted and more effective treatment options. For instance, according to ClinicalTrials.gov, a US-based clinical trial registry, there were 477,225 clinical trials registered globally by the end of 2023, up from 437,506 trials registered in 2022. Thus, the rising number of clinical trials is contributing to the growth of the desmoplastic small round cell tumor treatment market.
Major companies operating in the desmoplastic small round cell tumor treatment market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Fresenius Kabi AG, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Gilead Sciences Inc., Amgen Inc., GlaxoSmithKline plc (GSK), Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Aurobindo Pharma Limited, Hikma Pharmaceuticals PLC, Zymeworks Inc., Blueprint Medicines Corporation, MacroGenics Inc., Exelixis Inc.
North America was the largest region in the desmoplastic small round cell tumor treatment market in 2023. The regions covered in the desmoplastic small round cell tumor treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the desmoplastic small round cell tumor treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The treatment for desmoplastic small round cell tumor (DSRCT) involves various medical approaches, including surgery, chemotherapy, and radiation therapy, aimed at managing and controlling the progression of this rare and aggressive cancer. These treatments are designed to target and limit the spread of cancerous cells, particularly in the abdominal region. A significant benefit of DSRCT treatment is its potential to reduce tumor size, enhance survival rates, and improve the overall quality of life for patients.
The primary types of treatments in the desmoplastic small round cell tumor market include immunotherapy, surgical operations, chemotherapy, and radiotherapy. Immunotherapy is a treatment method that utilizes the body’s immune system to combat diseases, especially cancer. The various drug classes involved comprise cytotoxic agents, targeted therapies, and immunomodulators, with multiple end users including hospitals, oncology clinics, and ambulatory surgical centers.
The desmoplastic small round cell tumor treatment market research report is one of a series of new reports that provides desmoplastic small round cell tumor treatment market statistics, including desmoplastic small round cell tumor treatment industry global market size, regional shares, competitors with a desmoplastic small round cell tumor treatment market share, detailed desmoplastic small round cell tumor treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the desmoplastic small round cell tumor treatment industry. This desmoplastic small round cell tumor treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The desmoplastic small round cell tumor treatment market includes revenues earned by entities by providing services such as immunotherapy, diagnostic imaging, and post treatment care, including rehabilitation and follow up monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The desmoplastic small round cell tumor treatment market size has grown strongly in recent years. It will grow from $3.42 billion in 2023 to $3.7 billion in 2024 at a compound annual growth rate (CAGR) of 8.3%. The growth observed during the historical period can be attributed to increased awareness of rare cancers, a rise in the number of clinical trials, enhanced funding for rare cancer research, greater availability of advanced diagnostics, and the expansion of immunotherapies and gene therapies.
The desmoplastic small round cell tumor treatment market size is expected to see strong growth in the next few years. It will grow to $5.11 billion in 2028 at a compound annual growth rate (CAGR) of 8.4%. The anticipated growth during the forecast period can be attributed to the increasing number of specialized treatment centers, the rise of personalized medicine, a greater use of combination therapies, more new drug approvals, and an uptick in healthcare expenditures on cancer treatment. Key trends expected in this period include the adoption of targeted therapies, the integration of advanced diagnostics, the implementation of personalized medicine, advancements in gene editing technologies, and the development of improved drug delivery systems.
The growing emphasis on personalized medicine is projected to drive the growth of the desmoplastic small round cell tumor (DSRCT) treatment market in the future. Personalized medicine involves tailoring healthcare to an individual’s unique genetic profile, lifestyle, and environment. It encompasses strategies such as pharmacogenomics, targeted therapies, and gene editing to deliver more precise and effective treatments. The increasing focus on personalized medicine is fueled by advancements in genomics, enhanced patient outcomes, and the potential for more targeted therapies. In the case of DSRCT, personalized medicine enables treatment strategies that are based on the specific genetic and molecular characteristics of the tumor, facilitating targeted therapies that enhance efficacy and minimize side effects. For example, the Personalized Medicine Coalition, a US-based professional membership organization, reported that in 2022, the approval of 12 new personalized medicines accounted for approximately 34% of all new therapies approved, indicating a significant increase compared to previous years. Thus, the heightened focus on personalized medicine is a key driver of the DSRCT treatment market.
Increased investment in oncology research is also expected to support the growth of the desmoplastic small round cell tumor treatment market in the future. The rise in funding for oncology research is driven by the increasing incidence of cancer worldwide, advancements in precision medicine, and the need for innovative treatments to enhance patient outcomes. Research in oncology contributes to the treatment of DSRCT by improving the understanding of the tumor's biology, leading to the development of targeted therapies and better treatment protocols that improve patient outcomes. For instance, the National Cancer Institute, a US-based organization, reported in June 2024 that its budget for fiscal year 2022 was approximately $6.8 billion, reflecting a 5.7% increase from the previous year. Therefore, the growing investment in oncology research is propelling the DSRCT treatment market.
The increasing number of clinical trials is anticipated to drive the growth of the desmoplastic small round cell tumor treatment market moving forward. Clinical trials involve human volunteers and assess the safety and efficacy of new medical treatments or procedures, aiming to collect scientific data on their appropriateness for human use. The rise in clinical trials is largely attributed to advancements in medical research, the growing burden of diseases, regulatory changes, the globalization of clinical research, increased patient advocacy and awareness, competition within the industry, technological advancements, and new funding opportunities. Clinical trials provide access to innovative therapies and evaluate the effectiveness of new treatments, thereby improving patient outcomes and promoting the development of targeted and more effective treatment options. For instance, according to ClinicalTrials.gov, a US-based clinical trial registry, there were 477,225 clinical trials registered globally by the end of 2023, up from 437,506 trials registered in 2022. Thus, the rising number of clinical trials is contributing to the growth of the desmoplastic small round cell tumor treatment market.
Major companies operating in the desmoplastic small round cell tumor treatment market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Fresenius Kabi AG, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Gilead Sciences Inc., Amgen Inc., GlaxoSmithKline plc (GSK), Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Aurobindo Pharma Limited, Hikma Pharmaceuticals PLC, Zymeworks Inc., Blueprint Medicines Corporation, MacroGenics Inc., Exelixis Inc.
North America was the largest region in the desmoplastic small round cell tumor treatment market in 2023. The regions covered in the desmoplastic small round cell tumor treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the desmoplastic small round cell tumor treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The treatment for desmoplastic small round cell tumor (DSRCT) involves various medical approaches, including surgery, chemotherapy, and radiation therapy, aimed at managing and controlling the progression of this rare and aggressive cancer. These treatments are designed to target and limit the spread of cancerous cells, particularly in the abdominal region. A significant benefit of DSRCT treatment is its potential to reduce tumor size, enhance survival rates, and improve the overall quality of life for patients.
The primary types of treatments in the desmoplastic small round cell tumor market include immunotherapy, surgical operations, chemotherapy, and radiotherapy. Immunotherapy is a treatment method that utilizes the body’s immune system to combat diseases, especially cancer. The various drug classes involved comprise cytotoxic agents, targeted therapies, and immunomodulators, with multiple end users including hospitals, oncology clinics, and ambulatory surgical centers.
The desmoplastic small round cell tumor treatment market research report is one of a series of new reports that provides desmoplastic small round cell tumor treatment market statistics, including desmoplastic small round cell tumor treatment industry global market size, regional shares, competitors with a desmoplastic small round cell tumor treatment market share, detailed desmoplastic small round cell tumor treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the desmoplastic small round cell tumor treatment industry. This desmoplastic small round cell tumor treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The desmoplastic small round cell tumor treatment market includes revenues earned by entities by providing services such as immunotherapy, diagnostic imaging, and post treatment care, including rehabilitation and follow up monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Desmoplastic Small Round Cell Tumor Treatment Market Characteristics3. Desmoplastic Small Round Cell Tumor Treatment Market Trends and Strategies32. Global Desmoplastic Small Round Cell Tumor Treatment Market Competitive Benchmarking33. Global Desmoplastic Small Round Cell Tumor Treatment Market Competitive Dashboard34. Key Mergers and Acquisitions in the Desmoplastic Small Round Cell Tumor Treatment Market
4. Desmoplastic Small Round Cell Tumor Treatment Market - Macro Economic Scenario
5. Global Desmoplastic Small Round Cell Tumor Treatment Market Size and Growth
6. Desmoplastic Small Round Cell Tumor Treatment Market Segmentation
7. Desmoplastic Small Round Cell Tumor Treatment Market Regional and Country Analysis
8. Asia-Pacific Desmoplastic Small Round Cell Tumor Treatment Market
9. China Desmoplastic Small Round Cell Tumor Treatment Market
10. India Desmoplastic Small Round Cell Tumor Treatment Market
11. Japan Desmoplastic Small Round Cell Tumor Treatment Market
12. Australia Desmoplastic Small Round Cell Tumor Treatment Market
13. Indonesia Desmoplastic Small Round Cell Tumor Treatment Market
14. South Korea Desmoplastic Small Round Cell Tumor Treatment Market
15. Western Europe Desmoplastic Small Round Cell Tumor Treatment Market
16. UK Desmoplastic Small Round Cell Tumor Treatment Market
17. Germany Desmoplastic Small Round Cell Tumor Treatment Market
18. France Desmoplastic Small Round Cell Tumor Treatment Market
19. Italy Desmoplastic Small Round Cell Tumor Treatment Market
20. Spain Desmoplastic Small Round Cell Tumor Treatment Market
21. Eastern Europe Desmoplastic Small Round Cell Tumor Treatment Market
22. Russia Desmoplastic Small Round Cell Tumor Treatment Market
23. North America Desmoplastic Small Round Cell Tumor Treatment Market
24. USA Desmoplastic Small Round Cell Tumor Treatment Market
25. Canada Desmoplastic Small Round Cell Tumor Treatment Market
26. South America Desmoplastic Small Round Cell Tumor Treatment Market
27. Brazil Desmoplastic Small Round Cell Tumor Treatment Market
28. Middle East Desmoplastic Small Round Cell Tumor Treatment Market
29. Africa Desmoplastic Small Round Cell Tumor Treatment Market
30. Desmoplastic Small Round Cell Tumor Treatment Market Competitive Landscape and Company Profiles
31. Desmoplastic Small Round Cell Tumor Treatment Market Other Major and Innovative Companies
35. Desmoplastic Small Round Cell Tumor Treatment Market Future Outlook and Potential Analysis
36. Appendix
Executive Summary
Desmoplastic Small Round Cell Tumor Treatment Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on desmoplastic small round cell tumor treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
- Assess the Russia - Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for desmoplastic small round cell tumor treatment? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The desmoplastic small round cell tumor treatment market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- the market characteristics section of the report defines and explains the market.
- the market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- the forecasts are made after considering the major factors currently impacting the market. These include:
- the impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
- the impact of higher inflation in many countries and the resulting spike in interest rates.
- the continued but declining impact of COVID-19 on supply chains and consumption patterns.
- Market segmentations break down the market into sub markets.
- the regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- the competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- the trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) by Type: Immunotherapy; Surgical Operation; Chemotherapy; Radiotherapy2) by Drug Class: Cytotoxic Agents; Targeted Therapies; Immunomodulators
3) by End User: Hospitals; Oncology Clinics; Ambulatory Surgical Centers
Key Companies Mentioned: Pfizer Inc.; Johnson & Johnson Services Inc.; F. Hoffmann-La Roche AG; Merck & Co. Inc.; AbbVie Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
The major companies profiled in this Desmoplastic Small Round Cell Tumor Treatment market report include:- Pfizer Inc.
- Johnson & Johnson Services Inc.
- F. Hoffmann-La Roche AG
- Merck & Co. Inc.
- AbbVie Inc.
- Bayer AG
- Sanofi S.A.
- Bristol-Myers Squibb Company
- AstraZeneca PLC
- Novartis AG
- Fresenius Kabi AG
- Takeda Pharmaceutical Company Limited
- Eli Lilly and Company
- Boehringer Ingelheim International GmbH
- Gilead Sciences Inc.
- Amgen Inc.
- GlaxoSmithKline plc (GSK)
- Teva Pharmaceutical Industries Ltd.
- Regeneron Pharmaceuticals Inc.
- Aurobindo Pharma Limited
- Hikma Pharmaceuticals PLC
- Zymeworks Inc.
- Blueprint Medicines Corporation
- MacroGenics Inc.
- Exelixis Inc
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 175 |
| Published | December 2024 |
| Forecast Period | 2024 - 2028 |
| Estimated Market Value ( USD | $ 3.7 Billion |
| Forecasted Market Value ( USD | $ 5.11 Billion |
| Compound Annual Growth Rate | 8.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 25 |
